DB:2DE

Stock Analysis Report

Executive Summary

Genprex, Inc. operates as a clinical-stage gene therapy company.

Risk Analysis

Earnings have declined by -50.19% per year over past 5 years

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

+ 1 more risk


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Genprex's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2DE's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

273.9%

2DE

-1.0%

DE Biotechs

1.7%

DE Market


1 Year Return

220.9%

2DE

6.2%

DE Biotechs

15.0%

DE Market

Return vs Industry: 2DE exceeded the German Biotechs industry which returned 6.2% over the past year.

Return vs Market: 2DE exceeded the German Market which returned 15% over the past year.


Shareholder returns

2DEIndustryMarket
7 Day273.9%-1.0%1.7%
30 Day1260.8%-2.3%0.8%
90 Day1107.9%7.8%3.7%
1 Year220.9%220.9%6.4%6.2%18.5%15.0%
3 Yearn/a49.0%47.3%17.1%6.9%
5 Yearn/a12.6%10.3%24.3%7.3%

Price Volatility Vs. Market

How volatile is Genprex's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Genprex undervalued compared to its fair value and its price relative to the market?

19.2x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 2DE's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 2DE's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 2DE is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 2DE is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2DE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2DE is overvalued based on its PB Ratio (19.2x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Genprex forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genprex has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Genprex performed over the past 5 years?

-50.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 2DE is currently unprofitable.

Growing Profit Margin: 2DE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 2DE is unprofitable, and losses have increased over the past 5 years at a rate of -50.2% per year.

Accelerating Growth: Unable to compare 2DE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2DE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 2DE has a negative Return on Equity (-330.23%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Genprex's financial position?


Financial Position Analysis

Short Term Liabilities: 2DE's short term assets ($3.6M) exceed its short term liabilities ($537.2K).

Long Term Liabilities: 2DE has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 2DE is debt free.

Reducing Debt: 2DE had no debt 5 years ago.


Balance Sheet

Inventory Level: 2DE has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 2DE's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2DE has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 2DE has less than a year of cash runway if free cash flow continues to reduce at historical rates of -56.9% each year


Next Steps

Dividend

What is Genprex's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 2DE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2DE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2DE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2DE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2DE's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

John Varner (62yo)

7.5yrs

Tenure

US$1,484,141

Compensation

Mr. John Rodney Varner is a co-founder of Genprex, Inc. and has been the Chief Executive Officer, Secretary and Chairman of the Board of Genprex, Inc. since August 2012. He served as President at Genprex,  ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD1.48M) is above average for companies of similar size in the German market ($USD412.37K).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
John Varner
Co-Founder7.5yrsUS$1.48m1.93% $2.1m
Julien Pham
President & COO1.8yrsUS$562.54k0.0018% $2.0k
Ryan Confer
Chief Financial Officer3.4yrsUS$1.51m0.26% $290.2k
Jack Roth
Chairman of Scientific & Medical Advisory Board0yrsno data2.98% $3.3m

3.4yrs

Average Tenure

42yo

Average Age

Experienced Management: 2DE's management team is considered experienced (3.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
John Varner
Co-Founder7.5yrsUS$1.48m1.93% $2.1m
Jack Roth
Chairman of Scientific & Medical Advisory Board0yrsno data2.98% $3.3m
James Rothman
Strategic Advisor to the Board of Directors7.6yrsno datano data
Robert Pearson
Independent Director7.6yrsUS$400.00kno data
Pasi Jänne
Member of Scientific & Medical Advisory Board0yrsno datano data
David Friedman
Independent Director7.5yrsUS$400.00kno data
Shu Kam Mok
Member of Scientific & Medical Advisory Board0yrsno datano data
George Simon
Member of Scientific & Medical Advisory Board0yrsno datano data

7.5yrs

Average Tenure

58yo

Average Age

Experienced Board: 2DE's board of directors are considered experienced (7.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.3%.


Top Shareholders

Company Information

Genprex, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Genprex, Inc.
  • Ticker: 2DE
  • Exchange: DB
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$119.197m
  • Listing Market Cap: US$109.936m
  • Shares outstanding: 27.85m
  • Website: https://www.genprex.com

Number of Employees


Location

  • Genprex, Inc.
  • Health Discovery Building
  • 1601 Trinity Street
  • Austin
  • Texas
  • 78712
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GNPXNasdaqCM (Nasdaq Capital Market)YesVoting Common StockUSUSDMar 2018
2DEDB (Deutsche Boerse AG)YesVoting Common StockDEEURMar 2018

Biography

Genprex, Inc. operates as a clinical-stage gene therapy company. The company engages in developing technologies for cancer patients based upon a proprietary technology platform. Its platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. The company’s lead product candidate, Oncoprex immunogene therapy for non-small cell lung cancer (NSCLC), has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex also block mechanisms that create drug resistance. The company was founded in 2009 and is headquartered in Austin, Texas. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/16 23:05
End of Day Share Price2020/02/14 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.